Transforming Wet AMD Treatment with Ixo-vec, an Intravitreal Gene Therapy
Time: 1:30 pm
day: Day Two
Details:
- Explore the innovative approach of Ixo-vec, which uses the AAV.7m8 capsid to deliver a gene encoding aflibercept, enabling continuous production of the VEGF antagonist after a single intravitreal injection
- Review the LUNA Phae 2 trial results, demonstrating the safety and efficacy of Ixo-vec in reducing the need for frequent anti-VEGF injections and maintaining visual and anatomical outcomes in patients with wet AMD
- Discuss the potential impact of Ixo-vec on patient quality of life, highlighting the reduced treatment burden and the promise of long-term vision preservation with a single treatment
